Annual meeting shows spike in attendance over 2003

Total attendance at this year's AUA annual meeting in San Francisco increasedby about 1,500 over last year's meeting in Chicago, according to unauditedstatistics released on Monday. As of Monday, total professional attendanceat the meeting was 11,538, compared with 10,031 at the 2003 meeting.

Related Videos

Related Content

Advertisement

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 25th 2024

Behavioral intervention may improve psychological distress after testicular cancer

Hannah Clarke

The study showed significant reductions in both anxiety and depressive symptoms following the intervention.

November 25th 2024

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Hannah Clarke

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.

Related Content

Advertisement

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 25th 2024

Behavioral intervention may improve psychological distress after testicular cancer

Hannah Clarke

The study showed significant reductions in both anxiety and depressive symptoms following the intervention.

November 25th 2024

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Hannah Clarke

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.